http://www.lsis.com/goto/r5/rss 2010-06-23T11:10:03+01:00 text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v5/%3B%97f%FA%15%7Cvz The U.S. Food and Drug Administration approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus (HIV). This assay is approved for use as an aid in the diagnosis of HIV-1/HIV-2 infection in adults including pregnant women. It is also the first assay for use as an aid in the diagnosis of HIV-1/HIV-2 infection in children as young as two years old. The highly sensitive assay is intended to be used as an aid in the diagnosis of HIV-1/HIV-2 infection, including acute or primary HIV-1 infection. Since it actually detects the HIV-1 virus (specifically the p24 antigen) in addition to antibodies to HIV, the ARCHITECT HIV Ag/Ab Combo assay can be used to diagnose (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v5/%3B%97f%FB%1Cuwx Every nine and a half minutes, someone in the United States is infected with HIV, and one out of every five of these individuals doesn't know it. To help stem the spread of this disease, the U.S. Food and Drug Administration (FDA) approved an innovative new diagnostic tool, which will allow patients to be diagnosed earlier than ever before. Abbott's ARCHITECT HIV Ag/Ab Combo assay is the first test approved in the United States that can simultaneously detect both HIV antigen and antibodies. HIV antigen is a protein produced by the virus immediately after infection, whereas antibodies are developed days later as the body works to fight off the infection. Studies have demonstrated that (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FB%1Cu%7C%7F LOUISVILLE, Colo.-(BUSINESS WIRE)-GHX and its participating suppliers and providers are on target to cut a total of $5 billion in healthcare costs in the next 5 years by improving supply chain efficiencies, visibility and trading partner collaboration. GHX provides technology and services to automate and optimize business processes throughout the healthcare supply chain, and has achieved its first-quarter goal of cutting more than $155.6 million in healthcare costs. For the past 10 years, GHX and its participating healthcare suppliers and providers have focused on cutting billions of dollars in waste from the healthcare supply chain The model GHX is utilizing to measure progress toward (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FB%1Ctys CAMBRIDGE, Mass. and CARLSBAD, Calif.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY): We and Isis congratulate Regulus on forming this important new alliance with sanofi-aventis. Regulus stands as the leader in the emerging field of microRNA therapeutics, and this new partnership reflects the high level of interest across the pharmaceutical industry for innovative medicines based on this new biology New Partnership Validates Alnylam and Isis Strategy for Shareholder Value Creation Regulus, Alnylam and Isis to Host Conference Call Webcast to Discuss Regulus-Sanofi-aventis Collaboration on June 22, 2010 at 8:30 a.m. ET (5:30 a.m. PT) Alnylam Pharmaceuticals, Inc. (Nasdaq: (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FB%10%7Bvz BACKGROUND: The interpretation of a positive IgM antibody result to human cytomegalovirus (HCMV) in a pregnant woman is of major importance for the correct management of the pregnancy. Determination of HCMV-specific IgG avidity is considered an useful approach for distinguishing IgM antibody due to primary HCMV infection from IgM antibody elicited during non-primary infection. OBJECTIVE: Comparative evaluation of eight commercial HCMV IgG avidity assays currently available in Europe. STUDY DESIGN: A panel of 198 sequential samples collected from 65 pregnant women at 0-90, 91-180, and 180 days after the onset of primary HCMV infection was retrospectively tested by Abbott, BioMérieux, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v5/%3B%97f%FB%10%7Dy%7D CARLSBAD, Calif.-(BUSINESS WIRE)-Regulus Therapeutics Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years. The alliance will initially focus on the therapeutic area of fibrosis. Regulus and sanofi-aventis will collaborate on (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v5/%3B%97f%FB%10%7Dyx HENRIETTA, NY-(Marketwire - June 22, 2010) - Highlighted Links http:/www.Sensividamedtech.com http:/www.cfsg1.com SensiVida Medical Technologies (PINKSHEETS: SVMT), a developer of painless diagnostic systems, today announced that it has stepped up its product development activities after raising the first $1.5M of their $10M Series A financing. This initial financing phase is being used to accelerate internal product development and fund commercialization activities with partners such as Wi Inc. (http:/www.marketwire.com/press-release/SensiVida-Medical-Technologies-Inc-Enters-Design-Development-Agreement-With-Wi-Inc-Advance-1269639.htm) and Dhurjaty Electronics Consulting LLC. Dhurjaty (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FB%11t%7C%7B NEEDHAM, Mass.-(BUSINESS WIRE)-Three leading scientists in the field of cardiac safety in pre-clinical drug development are gathering to discuss Improved Strategies for Pre-clinical Cardiac Testing in a free webinar on June 23 at 11:00 a.m. EDT, sponsored by the Drug Safety Council (DSEC). most trusted and most used fee-for-service provider The panel features Arthur œBuzz  Brown, M.D., Ph.D., founder, president and CEO of ChanTest www.chantest.com, David J. Gallacher, BSc., Ph.D. senior director, Center of Excellence for Cardiovascular Safety Research, Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica, Belgium www.jnjpharmarnd.com, and Gary (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v5/%3B%97f%FB%11%7Bx%7E ABBOTT PARK, Ill., June 21 /PRNewswire-FirstCall/ - Every nine and a half minutes, someone in the United States is infected with HIV, and one out of every five of these individuals doesn't know it. To help stem the spread of this disease, the U.S. Food and Drug Administration (FDA) today approved an innovative new diagnostic tool, which will allow patients to be diagnosed earlier than ever before. Abbott's ARCHITECT HIV Ag/Ab Combo assay is the first test approved in the United States that can simultaneously detect both HIV antigen and antibodies. HIV antigen is a protein produced by the virus immediately after infection, whereas antibodies are developed days later as the body works to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FB%11xxs Coronary artery disease (CAD) continues to be a leading cause of death in the USA and throughout the world. Allina Health System, with the Minneapolis Heart Institute at Abbott Northwestern, recently announced a long-term study in the city of New Ulm, MN, to reduce risk factors for myocardial infarction and, ultimately, reduce myocardial infarction incidence. To achieve this goal, the focus will be on health promotion interventions and primary and secondary prevention strategies for CAD that are innovative, community-wide, and able to impact individuals at home, at work, in their community, and in their health care settings. Factors considered in selecting this city included the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FB%16u%7B%7C Multiple clinical trials have been performed to test the hypothesis that administration of bone-marrow-derived progenitor and stem cells (BMCs) may improve left-ventricular (LV) function following acute myocardial infarction (AMI). These studies have generally confirmed that cell therapy administration can be safely administered; however, consensus has not been reached on whether this approach results in an improvement in LV function or clinical outcomes. Although many of the published studies have been randomized, placebo-controlled trials, many important questions regarding patient selection, methodology and trial design still exist. To date, almost no information has been obtained in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FB%16uw%7C alpha3-containing (alpha3*) and alpha7 nicotinic acetylcholine receptors (nAChRs) are expressed in human IMR-32 neuroblastoma cells and implicated in Ca(2+) signaling. In this study, we investigated the intracellular Ca(2+) transient generation evoked by selective activation of alpha3* (agonist potency rank order: epibatidine varenicline nicotine approximately cytisine) and alpha7 (rank order in the presence of alpha7 positive allosteric modulator or PAM: A-795723 NS6784 approximately PNU-282987) using, respectively, varenicline and NS6784 (+ alpha7 PAM) by Ca(2+) imaging. Effects of inhibitors of nAChRs (MLA and mecamylamine), ER Ca(2+) ATPase pump (CPA and thapsigargin), Ca(2+) induced (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FB%16t%7Ex Nature. |-| Abbott A. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FB%16%7Ex%7B Nature. |-| Abbott A, Cyranoski D, Jones N, Maher B, Schiermeier Q, Van Noorden R. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FB%17%7F%7Cx Hodges & Sargent (2001) developed a measure of a hierarchical model's complexity, degrees of freedom (DF), that is consistent with definitions for scatterplot smoothers, interpretable in terms of simple models, and that enables control of a fit's complexity by means of a prior distribution on complexity. DF describes complexity of the whole fitted model but in general it is unclear how to allocate DF to individual effects. We give a new definition of DF for arbitrary normal-error linear hierarchical models, consistent with Hodges & Sargent's, that naturally partitions the n observations into DF for individual effects and for error. The new conception of an effect's DF is the ratio of the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FB%14ywr Nature. |-| Abbott A. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v5/%3B%97f%FB%14%7Fzr Mymetics Corporation, a pioneer in the development of vaccines preventing early transmission of human infectious diseases, announced that its innovative Malaria vaccine has successfully completed a Phase Ib clinical trial in Tanzania. The study confirms that the company's virosome-based vaccine is well tolerated and safe for adults and children as young as 5 years of age. The vaccine induced specific, long-lasting antibody responses against the key AMA-1 and CSP-1 Malaria antigens in semi-immune subjects, lasting up to 12 months for CSP-1. Mymetics' Malaria vaccine uses influenza-based virosomes as the antigen carrier - already approved as a vaccine carrier in more than 40 countries - with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FB%14%7E%7F%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d7d20e/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition" report to their offering. Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FC%1C%7D%7Fy The manufacture of a blend containing the active pharmaceutical ingredient (API) and inert excipients is a precursor for the production of most pharmaceutical capsules and tablets. However, if there is a net water gain or preferential loss of API during production, the potency of the final drug product may be less than the target value. We use a mass balance to predict the mean potency loss during the production of a blend via wet granulation and fluidized bed drying. The result is an explicit analytical equation for the change in blend potency a function of net water gain, solids losses (both regular and high-potency), and the fraction of excipients added extragranularly. This model (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v5/%3B%97f%FC%12%7B%7Er Jean-Louis Anspach, President, Eurand Pharmaceuticals, Inc. AMSTERDAM, THE NETHERLANDS-(Marketwire - June 16, 2010) - Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the appointment of Jean-Louis Anspach as President, Eurand Pharmaceuticals, Inc. (EPI). Anspach is a 25-year veteran of the specialty pharmaceutical and chemical industries and was most recently Executive Vice President, Marketing at Solvay Pharmaceuticals, Inc. (acquired by Abbott Laboratories in February 2010). He will be based at EPI's commercial headquarters in Yardley, Pa. "We are delighted to welcome Jean-Louis to the Eurand team," said Gearóid Faherty, Chairman and Chief (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v5/%3B%97f%FC%12zvy EPALINGES, SWITZERLAND-(Marketwire - June 17, 2010) - Mymetics Corporation, a pioneer in the development of vaccines preventing early transmission of human infectious diseases, announced today that its innovative Malaria vaccine has successfully completed a Phase Ib clinical trial in Tanzania. The study confirms that the company's virosome-based vaccine is well tolerated and safe for adults and children as young as 5 years of age. The vaccine induced specific, long-lasting antibody responses against the key AMA-1 and CSP-1 Malaria antigens in semi-immune subjects, lasting up to 12 months for CSP-1. Mymetics' Malaria vaccine uses influenza-based virosomes as the antigen carrier - already (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v5/%3B%97f%FC%12%7Fvy Abbott and Neurocrine Biosciences, Inc. announced they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids. "Extensive preclinical and clinical experience with elagolix suggests this drug could be an important advance for women with endometriosis and uterine fibroids, highly prevalent conditions where there is a need for new treatments," said John Leonard, M.D., (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FC%12%7E%7Dx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f119e5/diabetes_care_devi) has announced the addition of the "Diabetes Care Devices Market In Brazil, Russia, India & China (BRIC)" report to their offering. Diabetes Care Devices Market In Brazil, Russia, India & China (BRIC) This market research report analyzes the diabetes care devices market in Brazil, Russia, India, and China (BRIC) over the period 2009-2014. The report categorizes the overall market for diabetes care devices into the submarkets for insulin pumps, self-monitoring blood glucose systems, and continuous glucose monitoring systems. The diabetes care devices market in BRIC nations was (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FC%12%7Dz%7B SAN DIEGO-(BUSINESS WIRE)-Nexus Dx today announced two organizational changes in their Commercial Operations team. Paul Benson steps into the newly created position of Senior Director of Corporate Accounts for North America. Paul will be responsible for extending Nexus Dx customer base and extending market access to Nexus Dx products by securing Group Purchasing Organization (GPO) contracts, developing corporate business-to-business commercial relationships, managing large national accounts and the Nexus Dx business in Canada. Paul most recently was the Senior Director of Sales for North America for the Company. Additionally, Scott has a great background in sales and marketing management (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FC%12%7D%7Cz NEW YORK-(BUSINESS WIRE)-The Blackstone Group (NYSE: BX) today announced that Arthur J. Higgins, former Chairman of the Board of Management of Bayer HealthCare AG, has joined the firm s dedicated healthcare group, Blackstone Healthcare Partners. With the addition of Arthur Higgins we have further strengthened Blackstone Healthcare Partners. They offer a unique value to companies wishing to access focused industry expertise of this group of leading healthcare stars along with capital to fund growth. At Blackstone, Mr. Higgins will join health care veterans Lodewijk de Vink and Doug Rogers in providing industry knowledge and expertise to private equity transactions. Blackstone Healthcare (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FC%10u%7Bs We report an investigation of interfacial physicochemical phenomena underlying adsorbate-induced ordering transitions in nitrile-containing liquid crystals (LCs) supported on surfaces coated with metal perchlorate salts. When the mass density of Al(ClO(4)(3) deposited onto a surface was low (0.39 +/- 0.03 ng/mm(2), we measured 20 mum thick films of nematic 4-cyano-4'-n-pentyl-biphenyl (5CB) to initially exhibit perpendicular (homeotropic) ordering, consistent with the influence of coordination interactions between the nitrile groups of 5CB and Al(3+) ions on the surface on the ordering of the LC. Furthermore, exposure of freshly prepared LC films to vapors of an adsorbate that (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FC%10%7F%7D%7C Ritonavir (RTV) and other protease inhibitors (PIs) used for the treatment of human immunodeficiency virus (HIV) infection are associated with elevated serum triglycerides (TG) and cholesterol in some patients. A rat strain (Sprague-Dawley or SD) commonly used in toxicology studies is not sensitive to RTV-induced hyperlipidemia, making mechanistic studies and the identification of novel, lipid-neutral PIs challenging. The objective of this study was to identify a rat strain that mirrors human PI-associated hyperlipidemia. RTV was administered at 100mg/kg/day for 5days to a panel of 14 rat strains estimated to cover approximately 86% of the known genetic variance in rats. Increased serum TG (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FC%16tws With 25 figures Summary Blood to the pelvic limb of the ostrich is provided by the external iliac and ischiatic arteries that arise from the descending aorta. The external iliac artery (a.) gave rise to the pubic a. that supplied the obturator muscles and continued as the femoral a. The femoral a. gave off three branches: (1) cranial coxal a. to muscles above the pre-acetabular ilium; (2) cranial femoral a. to muscles cranial to the femur, the gastrocnemius muscle, hip and stifle joints and (3) medial femoral a. to muscles caudal and medial to the femur. The ischiatic a. gave rise to the caudal coxal a. that supplied muscles caudal to the femur, muscular branches to the iliotibialis (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FC%15t%7Er PURPOSE After the National Institutes of Health Consensus Statement in 1990, breast-conserving surgery (BCS) became more common while mastectomy rates decreased. However, several recently published single-institution studies have reported an increase in mastectomy rates in the past decade. We conducted a population-based study to evaluate national trends in the surgical treatment of breast cancer from 2000 through 2006. PATIENTS AND METHODS Using the Surveillance, Epidemiology, and End Results database, we conducted a retrospective cohort analysis of women undergoing surgical treatment for breast cancer. We evaluated variation in mastectomy rates by demographic and tumor factors and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FC%15%7Fv%7B Prev Sci. |-| Oesterle S, Hawkins JD, Fagan AA, Abbott RD, Catalano RF. |-| Social Development Research Group, University of Washington, 9725 3rd Ave. NE, Suite 401, Seattle, WA, 98115, USA, soe@uw.edu. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FC%15%7Cvz J Nucl Cardiol. |-| Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, Difilippo FP, Ficaro EP, Freeman MR, Hendel RC, Jain D, Leonard SM, Nichols KJ, Polk DM, Soman P. |-| Northwestern University, Chicago, IL, USA. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v5/%3B%97f%FD%1C%7B%7By ABBOTT PARK, Ill. and SAN DIEGO, June 16 /PRNewswire-FirstCall/ - Abbott and Neurocrine Biosciences, Inc. (Nasdaq:NBIX - News) today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids. "Extensive preclinical and clinical experience with elagolix suggests this drug could be an important advance for women with endometriosis and uterine fibroids, (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v5/%3B%97f%FD%1Cz%7B%7D Highlighted Links Blue Chip Patient Recruitment NORTHBROOK, IL-(Marketwire - June 15, 2010) - Blue Chip, an independent, full-service global marketing agency, announced today the launch of Blue Chip Patient Recruitment (BCPR), a division dedicated to serving pharmaceutical and biotech clients with clinical trial recruitment marketing. This new division reflects Blue Chip's 15 years of continued growth in patient recruitment and leverages the resources of a full-service agency with deep expertise in direct response media, retail brand marketing and clinical site recruitment management. BCPR's first client is BioSante Pharmaceuticals, Inc. "We are pleased to launch the new division with a (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FD%1Cxw%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/50d0ea/brazil_cardiovascu) has announced the addition of GlobalData's new report "Brazil Cardiovascular Devices Market Outlook to 2016" to their offering. Brazil Cardiovascular Devices Market Outlook to 2016 Our medical equipment report, Brazil Cardiovascular Devices Market Outlook to 2016 provides key market data on the Brazil cardiovascular devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories - Interventional Cardiology, Peripheral Vascular Devices, Cardiac Rhythm Management, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FD%1C%7Fvr ALLENDALE, N.J. & CORK, Ireland-(BUSINESS WIRE)-Eisai Machinery U.S.A. Inc. of Allendale, New Jersey, one of the world s leading pharmaceutical equipment manufacturers, and Crest Solutions of Cork, Ireland, a software and solution provider to both the medical device and pharmaceutical industries, today announced the launch of PharmaMarker ¢, a new track and trace packaging system for pharmaceutical products. The PharmaMarker system was developed to help pharmaceutical manufacturers meet the challenges of more stringent local and international regulations in the areas of coding and traceability of pharmaceutical products. The PharmaMarker is an easy-to-integrate, easy-to-validate (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FD%13y%7Br PURPOSE:To report 1-year follow-up in 11 of 13 eyes with keratoconus treated by deep anterior lamellar keratoplasty with a combined femtosecond laser lamellar resection followed by a big-bubble dissection. METHODS:Thirteen eyes with keratoconus were treated. Recipient and donor were prepared with the 60-kHz IntraLase femtosecond laser (Abbott Medical Optics). In the recipient, the femtosecond laser, after performing a lamellar cut 100 mum above the thinnest corneal point (measured by Pentacam [Oculus Optikgeräte GmbH]), was used to make a mushroom-shaped resection (anterior diameter, 9 mm; posterior diameter, 8 mm) from the same depth. In the donor, the mushroom lamellar thickness was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FD%13x%7D%7D The aim of this study is to assess the effective measurement range of Ryff's Psychological Well-being scales (PWB). It applies normal ogive item response theory (IRT) methodology using factor analysis procedures for ordinal data based on a limited information estimation approach. The data come from a sample of 1,179 women participating in a midlife follow-up of a national birth cohort study in the UK. The PWB scales incorporate six dimensions: autonomy, positive relations with others, environmental mastery, personal growth, purpose in life and self-acceptance. Scale information functions were calculated to derive standard errors of measurement for estimated scores on each dimension. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FD%10xz%7E Aims: The aim of this randomised study is to evaluate the efficacy and safety of a new bare metal stents (BMS) with thin struts and a novel passive coating as compared to current standard BMS.Methods and results: We designed an international, multicentre, randomised trial planned to include 160 patients assigned to receive either the titanium-nitride coated MAR-tyn stent (International Biomedical Systems, Trieste, Italy) or the Vision stent (Abbott Vascular, Abbott Laboratories, Abbott Park, IL, USA). Patients with left main or bypass graft disease, complex coronary lesions, needing treatment of multiple lesions, with recent myocardial infarction, prior BMS in or within 5 mm of the target (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FD%10y%7F%7D PURPOSE:To evaluate and compare the outcome of initial resident surgical experience with photorefractive keratectomy (PRK) and LASIK. METHODS:Retrospective review of all cases performed with the VISX Star S4 platform (Abbott Medical Optics) between July 1, 2003 and June 30, 2007. Inclusion criteria were spherical equivalent of -0.50 to -10.00 diopters (D), refractive astigmatic error of text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FD%10%7Fw%7F ABSTRACT: BACKGROUND: Laser microdissection (LMD) has been established for isolation of individual tissue types from herbaceous plants. However, there are few reports of cell- and tissue-specific analysis in woody perennials. While microdissected tissues are commonly analyzed for gene expression, reports of protein, enzyme activity and metabolite analysis are limited due in part to an inability to amplify these molecules. Conifer stem tissues are organized in regular patterns with xylem, phloem and cortex development controlled by the activity of the cambial zone (CZ). Defense responses of conifer stems against insects and pathogens involve increased accumulation of terpenoids in cortical (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FD%10%7Dys BACKGROUND: Abbott RealTime (RT) High-Risk (HR) HPV assay is a new qualitative real-time polymerase chain reaction (PCR) based assay for the detection of 14 HR HPV DNA. The assay can differentiate between the infection by HPV 16, HPV 18 and non-HPV 16/18 types through the distinct fluorescent labels on the type specific probes. OBJECTIVES: To evaluate the clinical performance of the Abbott RT HR HPV test, in comparison with biopsy, Hybrid Capture II (HCII), and Linear Array (LA), for detection of high-grade disease (CIN2+). STUDY DESIGN: The study population consisted of 143 women who were included in three referral gynecology clinics in Marseilles (France) between March 2007 and June (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v5/%3B%97f%FD%11%7B%7Ex PURPOSE:To present a patient in whom, during LASIK with the IntraLase femtosecond laser (Abbott Medical Optics), unintended epithelial (instead of anterior stromal) flaps were created in both eyes. METHODS:A 28-year-old man underwent bilateral LASIK using the IntraLase femtosecond laser programmed to create 100-mum flaps. Flap creation was performed uneventfully in both eyes but flap thickness was thinner than attempted. The flaps were easily torn during flap lift because they appeared to consist of epithelium only. Therefore, the procedure was immediately converted to photorefractive keratectomy with the use of mitomycin C. RESULTS:Re-epithelialization occurred 3 days after the procedure (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v5/%3B%97f%FD%11yw%7E ALAMEDA, Calif., Jun 15, 2010 (BUSINESS WIRE) - Celera Corporation today confirmed that a purported class action lawsuit was filed against the Company and certain of its officers and announced on June 14, 2010. The lawsuit alleges that during the period from April 24, 2008 through July 22, 2009, the Company issued false and misleading statements regarding the Company's business and financial results, and seeks unspecified damages on behalf of an alleged class of purchasers of the Company's stock during this period. Celera believes that the allegations are without merit and intends to vigorously defend the action. About Celera Celera is a healthcare business focusing on the integration of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v5/%3B%97f%FD%11yx%7F BNET - Good news, bad news for Abbott Labs ˜ (ABT) pharmaceutical sales reps: They recently won a court ruling that paves the way for an award of backpay for unpaid overtime, but they re also bracing for another round of layoffs, possibly on June 30. text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v5/%3B%97f%FD%11xv%7F ROCKVILLE, MD-(Marketwire - June 14, 2010) - MarketResearch.com has announced the addition of Kalorama Information's new report "The Global Market for Medical Devices," to their collection of Medical Devices market reports. For more information, visit http:/www.marketresearch.com/product/display.asp?ProductID=2592223. The medical device market is vast and everything from a large imaging system to a disposable item can be classified as a type of medical device. Throughout the past decade, Kalorama has covered many device markets in detail. Certain areas such as infusion pumps, patient monitoring and catheters have shown promising growth. Others have solid market leaders earning stable (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v5/%3B%97f%FD%11%7Fz%7E Nearly nine in 10 people think feeling weaker is one of the worst parts about aging, according to a recent survey commissioned by Abbott (NYSE: ABT) and developed in conjunction with the AGS Foundation for Health in Aging, a nonprofit dedicated to the health and well-being of older adults, which provided expert, independent review. But while 70 percent of Americans say they are concerned about muscle loss, close to 90 percent of Americans over the age of 45 are not taking critical steps, like making both daily exercise and proper nutrition part of their daily routines, to protect their muscles as they get older. "Muscle loss is a serious issue that can lead to severe health and lifestyle (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FD%11%7F%7Es DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/86b7d0/opportunities_in_e) has announced the addition of the "Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas" report to their offering. Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas Pharmaceuticals, Generics, Vaccines, OTCs, Hepatitis and HIV/AIDS agents and Biosimilars appropriate for the Emerging markets. Other companies still seeking alliances are identified, as well as those that appear to be potential generic and Biosimilar supply partners. This report provides market (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FD%11%7F%7E%7E LOS ANGELES-(BUSINESS WIRE)-AIDS Healthcare Foundation: Drug spending by ADAPs has increased more than seven-fold (617%) since 1996, more than twice the rate of client growth over this same period. WHAT: PROTEST Re: BMS Pricing of AIDS Drug, Reyataz, one of the most expensive first line AIDS treatments in the US WHEN: TUESDAY, June 15th, 10:00 AM Pacific WHERE: outside the Goldman Sachs Global Healthcare Conference 2010 Hyatt Regency Century Plaza Hotel 2025 Avenue of the Stars Century City, CA VISUALS: 3ft x 6ft œShame on BMS  and œHow do you spell GREED? BMS  banners & placards with image of CEO Andreotti surrounded by Piles of Cash Protestors, marching with signs and chanting (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FD%11%7Ezs DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c1a00d/global_molecular_d) has announced the addition of the "Global Molecular Diagnostics Market 2009-2013" report to their offering. Molecular Diagnostics is the clinical application of molecular biology technologies, used in disease management. It consists of screening and diagnostics tests - using genetic material (DNA and RNA). Further, the Molecular Diagnostics tests facilitate early diagnosis of a disease, therapeutic efficacy of drugs, genetic predisposition to disease, and prediction of individual's response to drug. Thus, the Molecular Diagnostics technologies offer the potential (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v5/%3B%97f%FD%11%7E%7Cx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1db693/stakeholder_opinio) has announced the addition of the "Stakeholder Opinions: Autoimmune Disorders in Emerging Markets - Patient Access Limits Market Potential" report to their offering. Stakeholder Opinions: Autoimmune Disorders in Emerging Markets - Patient Access Limits Market Potential Autoimmune diseases offer a growth opportunity for companies. Emerging markets are also a key focus, providing a large patient pool and huge potential. However, market potential is not directly proportional to patient potential. Recognizing issues with patient access, cost and affordability are vital to (…)